Background
==========

With an estimated 300 million individuals affected worldwide, asthma is associated with substantial social and economic burden. The cost of treating uncontrolled severe allergic asthma (SAA) is high encompassing a variety of direct medical costs and indirect costs. We present data on real-world healthcare utilization (direct) and school/work absence (indirect) in uncontrolled SAA patients receiving omalizumab in the eXpeRience registry.

Methods
=======

eXpeRience was a 2-year, global, single-arm, observational registry. Data were collected on real-world effectiveness, safety and use of omalizumab in patients with uncontrolled SAA. Asthma-related healthcare utilization (hospitalizations, emergency room visits or unscheduled doctor visits) and number of days missed from school/work were recorded.

Results
=======

The intent-to-treat population comprised 916 (97.1%) patients. Compared with the pre-treatment period, there were reductions in healthcare utilization and school/work absence after 12 and 24 months of omalizumab treatment.

  Variable, mean (SD); n                                 Pre-treatment**°** (N=916)   12 months (N=734)   24 months (N=643)
  ------------------------------------------------------ ---------------------------- ------------------- -------------------
  Asthma-related hospitalizations                        0.7 (1.32); 882              0.1 (0.43); 702     0.1 (0.41); 628
  Duration of hospitalization stay due to asthma, days   5.3 (11.05); 852             0.7 (3.84); 703     0.5 (3.39); 628
  Asthma-related emergency room visits                   1.8 (2.87); 867              0.2 (0.64); 700     0.1 (0.32); 627
  Unscheduled asthma-related doctor visits               3.8 (4.79); 823              0.7 (1.43); 684     0.4 (0.99); 619
  Asthma-related medical healthcare uses\*               6.2 (6.97); 811              1.0 (1.96); 684     0.5 (1.28); 618
  Absence from work due to asthma^\#^, days              26.4 (49.61); 347            3.5 (17.28); 295    1.0 (4.66); 296
  Absence from school due to asthma^\#^, days            20.7 (27.49); 57             1.6 (4.28); 59      1.9 (5.46); 58

Table [1](#T1){ref-type="table"} shows annualized data (12 month combined 16 weeks, 8 and 12 month data; 24 month combined 18 and 24 month data).

n **--** number of patients with data recorded. **°**Within 12 months prior to start of omalizumab treatment. \*Total number of asthma-related healthcare uses was calculated if data for asthma-related hospitalizations, emergency room visits and unscheduled doctor visits were available. ^\#^Excluded those patients for whom this category was not applicable. Conclusion: Results from the eXpeRience registry showed that omalizumab reduced healthcare utilization and the number of days missed from school or work by asthma patients in a real-world setting. Thus, omalizumab treatment was associated with a positive and substantial impact on the direct and indirect costs linked with uncontrolled SAA.
